Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Zymeworks and keeping the price target at $32.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles Zhu has given his Buy rating due to a combination of factors that highlight Zymeworks’ promising advancements and financial stability. The company has demonstrated validation of its Antibody-Drug Conjugate (ADC) platform through positive data from its potential best-in-class FRa ZW191, which is undergoing dose optimization. This progress, alongside the anticipated topline results from the HERIZON-GEA study by the end of 2025, underscores the company’s robust pipeline and strategic alignment with regulatory strategies.
Additionally, Zymeworks is capitalizing on its diverse revenue streams from existing partnerships, such as those involving zanidatamab and pasritamig, which are expected to contribute significantly to its financial health. The management’s fiscal discipline, combined with a strong cash position of $299 million as of September 2025, provides a solid foundation for future growth and shareholder value. These elements collectively support the Buy rating as Zymeworks continues to advance its innovative therapies and expand its market opportunities.